Royalty Report: Drugs, Cancer, Therapeutic – Collection: 28618


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28618

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, royalty-bearing license in the Territory, with the right to sublicense, under Celgene Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor to develop, make, have made, use, sell, offer for sale and import Products in all Fields of Use, and non-exclusive, non-transferable, royalty-free research license in the Territory under Licensor Patent Rights, Licensor's interest in Joint Patent Rights and Know-How of Licensor solely for the purpose of conducting research on Research Compounds, Active Compounds, Candidate Compounds, Final Selected Compounds and Back-Up Compounds in all Fields of Use; provided, however, that

Licensor and its Affiliates developed expertise and acquired proprietary rights related to selective estrogen receptor modulator compounds ('SERMS') which are selective for Estrogen Receptor ('ER')(alpha) ('ER(alpha)') in U2OS cells (the 'ER(alpha)SELECTIVITY'

License Property
SP500263  Series  shall mean  Licensor's  proprietary  compounds claimed in U.S. Patent Application  Serial No.  09/475,776
Field of Use
Additional Field shall mean the treatment, prevention and diagnosis of a disease or disorder, other than a disease or disorder within the Primary Field or the Oncology Field.

IPSCIO Record ID: 289168

License Grant
The Parties will collaborate in the discovery, development and commercialization of products for use in the prevention, and/or treatment of certain human diseases.

Licensor grants Licensee under the Licensor Patents, Licensor Know-How and Licensors interest in the Research Technology and the Research Technology Patent Rights
— a non-exclusive, worldwide, right and license, without the right to sub license, solely to conduct its Research activities pursuant to this Agreement during the Research Term; and
— if Licensee exercises its License Option, commencing at the expiration of the Research Term and for a period of 3 years thereafter, a non-exclusive, worldwide,  right and license, with the right to sub license solely to optimize, and, in connection with Licensees activities under this Agreement, make and use, but not sell, offer for sale or import, solely in connection with such optimization, Released Compounds for use in the Field.

Licensor grants Licensee an exclusive option during, the 4 month period following each decision by Licensor not to advance any particular Candidate Compound as either a Clinical Development Compound or Back-Up Compound, to obtain an exclusive, including with regard to Licensor, world-wide, right and license, with the right to sublicense, under the Licensor Patents and Licensor Know-How solely to conduct development on, and to make, have made and use for such purpose, any such Released Compounds for use in the Field, and to make, have made, import, use, sell and offer for sale pharmaceutical products containing or comprising any such Released Compounds in any formulation, each, a Released Product, for use in the Field.

License Property
Licensor is engaged in the research, development and marketing of products for the treatment of, among other things, diseases within the field of cancer.

Licensed Product means any product, including any formulation thereof, containing or comprising a Clinical Development Compound for use within the Field.

Licensor will initially provide Licensee with approximately [0.5 micromoles] each of approximately four hundred thousand (400,000) compounds, each an Licensor Compound in a 384 well format.

Field of Use
Field means any and all uses for the prevention or treatment of human disease. Licensee and its Affiliates possess proprietary technology and know-how related to modulation of caspases.

Caspases are a family of protease enzymes playing essential roles in programmed cell death.

IPSCIO Record ID: 203285

License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.

6,670,386 – Bicyclic modulators of androgen receptor function

The licensed compounds and patents relate to controlling various diseases and cancers.

Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.

IPSCIO Record ID: 203240

License Grant
Pursuant to this Agreement, Licensor will undertake and be responsible for the conduct of the Research Program, the Early Development Program(s) and all PoC Trials.

For commercialization, Licensor grants to the Licensee of England, the exclusive, right and license in the Territory, with the right to grant sublicenses, under all of Licensors rights, title and interest in and to the Licensors Technology, to make, have made, use, sell, offer for sale and import the Progressed Compounds which are the subject of each of such Product Options as and into Product Candidates and as and into Licensed Products in the Field during the Term of this Agreement.

For Trademarks for licensed Products, Licensor shall assign its rights and title to such trademark(s) to Licensee, upon request.

Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect to obtain exclusive worldwide rights to continue to develop and commercialize at least four (4) and no more than six (6) Option Compounds (and their associated Back-up Compounds), as Product Candidates and into Licensed Products.

License Property
Licensor possesses proprietary technology and know-how related to the research, discovery, identification, synthesis and development of small molecule drug candidates targeting certain chemokine receptors.  CCR9 shall mean that certain chemokine receptor.

The patents include Sulfonamides, Piperazines and derivatives for inflammation and immunes.

Traficet-EN is intended to control the inflammatory response underlying inflammatory bowel disease, or IBD, by targeting the chemokine receptor known as CCR9. In adults, CCR9 is found primarily on a population of T cells, a subset of the body’s inflammatory cells, that migrate selectively to the digestive tract.

CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of RA patients contains high levels of activated CCR1 chemokine ligands. Blocking CCR1 is intended to reduce inflammation and prevent subsequent joint destruction by suppressing the infiltration of inflammatory cells into the arthritic joint.

Traficet-EN (CCX282 or GSK’786) — Our most advanced drug candidate, currently in three pivotal Phase III clinical trials being conducted by our partner for the treatment of patients with moderate-to-severe Crohn’s disease.

Field of Use
Licensee possesses expertise in the pharmaceutical research, development, manufacturing and commercialization of human pharmaceuticals, and Licensee is interested in developing such small molecule drug candidates as drug products;

Field shall mean any use or purpose, including without limitation the treatment, palliation, and/or prevention of any human or animal disease, disorder or condition; provided, however, that the Field shall specifically exclude the commercialization of protein therapeutics directed against Collaboration Targets.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.